Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Tom T. Shimabukuro; Matt Cole; John R. Su

doi:10.1001/jama.2021.1967

February 12, 2021JAMAOpen Access

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

View Full Paper

Ask AI

Bookmark

Share

Key Points

The review aims to detail the cases of anaphylaxis reported following the administration of mRNA COVID-19 vaccines in the US.
Reviewed clinical details of anaphylactic reactions reported to and verified by the CDC.
Focused on reactions after Pfizer-BioNTech and Moderna COVID-19 vaccines.
Data collected during the period of December 14, 2020, to January 18, 2021.
Identified a number of anaphylaxis cases associated with the mRNA vaccines.
All reported cases were verified by the CDC, confirming the adverse events.
The timing and clinical characteristics of the reactions provided insights into vaccine safety.

Implication

Insights review details anaphylactic reactions in the early use of mRNA COVID-19 vaccines, indicating safety concerns.

Abstract

This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTech and Moderna COVID-19 vaccines in the US, December 14, 2020-January 18, 2021.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shimabukuro et al. (2021) studied this question.

synapsesocial.com/papers/6a3b1eb6cc8dbc104a21ba9b https://doi.org/10.1001/jama.2021.1967

View Full Paper

Ask AI

Bookmark

Share

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Key Points

Implication

Abstract

Discussion

Cite This Study

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading